1. Homepage
  2. Equities
  3. Sweden
  4. Nasdaq Stockholm
  5. Ascelia Pharma AB (publ)
  6. News
  7. All News
    ACE   SE0010573113

ASCELIA PHARMA AB (PUBL)

(ACE)
  Report
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
SummaryMost relevantAll NewsOther languagesPress ReleasesOfficial PublicationsSector news
All news about ASCELIA PHARMA AB (PUBL)
05/11TRANSCRIPT : Ascelia Pharma AB, Q1 2022 Earnings Call, May 11, 2022
CI
05/11QUARTERLY REPORT Q1 2022 : Strong Orviglance support from healthcare professionals
AQ
05/11Ascelia Pharma AB Reports Earnings Results for the First Quarter Ended March 31, 2022
CI
05/10Ascelia Pharma's Food Effect Study shows that Orviglance image enhancement of the liver..
AQ
05/10Ascelia Pharma's Food Effect Study Shows Orviglance Image Enhancement of the Liver Is N..
CI
05/05Bulletin from the Annual General Meeting in Ascelia Pharma AB on 5 May 2022
AQ
05/05Ascelia Pharma AB Announces Resignation of Bo Jesper Hansen as Board Member
CI
04/11Ascelia Pharma publishes Annual Report for 2021
AQ
04/05Notice of annual general meeting in ascelia pharma ab
AQ
04/01CFO Kristian Borbos to leave Ascelia Pharma
AQ
03/31Number of shares and votes in Ascelia Pharma AB
AQ
03/31HC ANDERSEN CAPITAL : Release of new Ascelia Pharma investment case
AQ
03/22New independent market research says 84% US healthcare professionals likely to use Orvi..
AQ
03/11Ascelia Pharma successfully completes Orviglance Hepatic Impairment Study
AQ
03/11Ascelia Pharma AB Successfully Completes Orviglance Hepatic Impairment Study
CI
03/07Ascelia Pharma suspends clinical activities in Russia
AQ
03/07Ascelia Pharma Suspends Clinical Activities in Russia
CI
03/02Issue and repurchase of series C shares for share saving program
AQ
02/15Results from Orviglance comparison study to gadolinium accepted for oral presentation a..
AQ
02/10TRANSCRIPT : Ascelia Pharma AB, 2021 Earnings Call, Feb 10, 2022
CI
02/10QUARTERLY REPORT Q4 2021 : Strong data for Orviglance vs. a gadolinium contrast agent
AQ
02/10Ascelia Pharma AB Reports Earnings Results for the Fourth Quarter and Full Year Ended D..
CI
2021Ascelia Pharma receives FDA acceptance of IND application for Oncoral clinical trial
AQ
2021Ascelia Pharma AB Receives FDA Acceptance of IND Application for Oncoral Clinical Trial
CI
2021Results from Orviglance comparison study to gadolinium presented at RSNA 2021
AQ
2021Ascelia Pharma AB Announces Results from Orviglance comparison study to gadolinium pres..
CI
2021Nomination Committee appointed for AGM 2022 in Ascelia Pharma AB
AQ
2021TRANSCRIPT : Ascelia Pharma AB, Nine Months 2021 Earnings Call, Nov 04, 2021
CI
2021QUARTERLY REPORT Q3 2021 : Oncoral – entering clinical collaboration
AQ
2021Ascelia Pharma AB Reports Earnings Results for the Third Quarter and Nine Months Ended ..
CI
2021ASCELIA PHARMA : Food Effect Study with Orviglance successfully completed
AQ
2021Ascelia Pharma AB Completes Food Effect Study with Orviglance Successfully
CI
2021ASCELIA PHARMA : Signs Clinical Collaboration Agreement With Taiho Oncology, Inc. for the ..
AQ
2021Ascelia Pharma Signs Clinical Collaboration Agreement With Taiho Oncology, Inc. for the..
CI
2021ASCELIA PHARMA AB(OM : ACE) added to S&P Global BMI Index
CI
2021Certain Ordinary Shares of Ascelia Pharma AB are subject to a Lock-Up Agreement Ending ..
CI
2021TRANSCRIPT : Ascelia Pharma AB, H1 2021 Earnings Call, Aug 19, 2021
CI
2021QUARTERLY REPORT Q2 2021 : Preparing Oncoral for the next level
AQ
2021Ascelia Pharma AB publ Announces Earnings Results for the Second Quarter Ended June 30,..
CI
2021ASCELIA PHARMA : Covid-19 extends recruitment period of SPARKLE study
AQ
2021Ascelia Pharma AB Announces That the Continued Global Impact of the Covid-19 Pandemic C..
CI
2021ASCELIA PHARMA : Abstract for Orviglance comparison study to gadolinium accepted at the wo..
AQ
2021Ascelia Pharma AB Announces Abstract for Orviglance Comparison Study to Gadolinium Acce..
CI
2021ASCELIA PHARMA : receives conditional FDA acceptance for brand name Orviglance
AQ
2021Ascelia Pharma AB Receives Conditional U.S. Food and Drug Administration Acceptance for..
CI
2021TRANSCRIPT : Ascelia Pharma AB, Q1 2021 Earnings Call, May 12, 2021
CI
2021QUARTERLY REPORT Q1 2021 : US office opened in preparation of launch
AQ
2021Ascelia Pharma AB Publ Reports Earnings Results for the First Quarter Ended March 31, 2..
CI
2021ASCELIA PHARMA : Bulletin from the Annual General Meeting in Ascelia Pharma AB on 5 May 20..
AQ
2021ASCELIA PHARMA : Number of shares and votes in Ascelia Pharma AB
AQ
2021ASCELIA PHARMA AB : publishes prospectus regarding admission to trading of newly issued sh..
AQ
2021ASCELIA PHARMA : Bulletin from the extraordinary general meeting in Ascelia Pharma AB
AQ
2021ASCELIA PHARMA : Issue and repurchase of series C shares for share saving program
AQ
2021ASCELIA PHARMA : Notice of annual general meeting in ascelia pharma ab
AQ
2021ASCELIA PHARMA : Number of shares and votes in Ascelia Pharma AB
AQ
2021ASCELIA PHARMA : publishes Annual Report for 2020
AQ
2021ASCELIA PHARMA : Notice of extraordinary general meeting in Ascelia Pharma
AQ
2021ASCELIA PHARMA : has carried out a directed new share issue raising SEK 200 million
AQ
2021ASCELIA PHARMA : intends to carry out a directed new share issue
AQ
2021ASCELIA PHARMA : opens US office in preparation for Mangoral launch
AQ
2021Ascelia Pharma AB Opens US Office in Preparation for Mangoral Launch
CI
2021TRANSCRIPT : Ascelia Pharma AB, 2020 Earnings Call, Feb 16, 2021
CI
2021QUARTERLY REPORT Q4 2020 : Mangoral shows high diagnostic value in new study
AQ
2021Ascelia Pharma AB Reports Earnings Results for the Fourth Quarter of 2020
CI
2021ASCELIA PHARMA : Information regarding transfer of shares in Ascelia Pharma AB from CMC SP..
AQ
2021ASCELIA PHARMA : presents clinical development plan for Oncoral as a novel chemotherapy
AQ
2021Ascelia Pharma AB Presents Clinical Development Plan for Oncoral as a Novel Chemotherap..
CI
2020ASCELIA PHARMA : gets US patent for second generation Mangoral
AQ
2020Ascelia Pharma Gets US Patent for Second Generation Mangoral
CI
2020ASCELIA PHARMA : New study shows Mangoral's lesion visualization as effective as gadoliniu..
AQ
2020Ascelia Pharma AB Announces New Study Shows Mangoral's Lesion Visualization as Effectiv..
CI
2020TRANSCRIPT : Ascelia Pharma AB, Nine Months 2020 Earnings Call, Nov 05, 2020
CI
2020QUARTERLY REPORT Q3-2020 : Raised market estimate for Mangoral and preparing for market la..
AQ
2020Ascelia Pharma AB Announces Earnings Results for the Third Quarter of 2020
CI
2020ASCELIA PHARMA : EMA confirms Mangoral eligible for the centralized regulatory procedure i..
AQ
1  2Next